These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23224976)

  • 1. Protected graft copolymer excipient leads to a higher acute maximum tolerated dose and extends residence time of vasoactive intestinal Peptide significantly better than sterically stabilized micelles.
    Reichstetter S; Castillo GM; Rubinstein I; Nishimoto-Ashfield A; Lai M; Jones CC; Banerjee AA; Lyubimov A; Bloedow DC; Bogdanov A; Bolotin EM
    Pharm Res; 2013 Mar; 30(3):670-82. PubMed ID: 23224976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles.
    Wernig K; Griesbacher M; Andreae F; Hajos F; Wagner J; Mosgoeller W; Zimmer A
    J Control Release; 2008 Sep; 130(2):192-8. PubMed ID: 18601963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo.
    Onyüksel H; Ikezaki H; Patel M; Gao XP; Rubinstein I
    Pharm Res; 1999 Jan; 16(1):155-60. PubMed ID: 9950295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All D-VIP mitigates vasodilation elicited by L-VIP, micellar L-VIP and micellar PACAP1-38, but not PACAP1-38, in vivo.
    Rubinstein I; Ashok B; Tsueshita T; Onyüksel H
    Peptides; 2005 Mar; 26(3):509-15. PubMed ID: 15652658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasoactive Intestinal Peptide Nanomedicine for the Management of Inflammatory Bowel Disease.
    Jayawardena D; Anbazhagan AN; Guzman G; Dudeja PK; Onyuksel H
    Mol Pharm; 2017 Nov; 14(11):3698-3708. PubMed ID: 28991483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting breast cancer using pirarubicin-loaded vasoactive intestinal peptide grafted sterically stabilized micelles.
    Eskandari Z; Bahadori F; Yapaoz MA; Yenigun VB; Celikten M; Kocyigit A; Onyuksel H
    Eur J Pharm Sci; 2021 Jul; 162():105830. PubMed ID: 33819623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical potential of VIP by modified pharmaco-kinetics and delivery mechanisms.
    Burian B; Ortner A; Prassl R; Zimmer A; Mosgoeller W
    Endocr Metab Immune Disord Drug Targets; 2012 Dec; 12(4):344-50. PubMed ID: 23094831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of peptide molecular mass and PEG chain length on the vasoreactivity of VIP and PACAP(1-38) in pegylated phospholipid micelles.
    Ashok B; Rubinstein I; Tsueshita T; Onyüksel H
    Peptides; 2004 Aug; 25(8):1253-8. PubMed ID: 15350692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog.
    Thakur ML; Aruva MR; Gariepy J; Acton P; Rattan S; Prasad S; Wickstrom E; Alavi A
    J Nucl Med; 2004 Aug; 45(8):1381-9. PubMed ID: 15299065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasoactive intestinal peptide encapsulated in liposomes: effects on systemic arterial blood pressure.
    Gao XP; Noda Y; Rubinstein I; Paul S
    Life Sci; 1994; 54(15):PL247-52. PubMed ID: 8152324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis.
    Koo OM; Rubinstein I; Onyüksel H
    Pharm Res; 2011 Apr; 28(4):776-87. PubMed ID: 21132352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colonic delivery of vasoactive intestinal peptide nanomedicine alleviates colitis and shows promise as an oral capsule.
    Dulari Jayawardena ; Arivarasu N Anbazhagan ; Priyamvada S; Kumar A; Saksena S; Onyuksel H; Pradeep K Dudeja
    Nanomedicine (Lond); 2020 Oct; 15(25):2459-2474. PubMed ID: 32975467
    [No Abstract]   [Full Text] [Related]  

  • 13. Conformation and vasoreactivity of VIP in phospholipids: effects of calmodulin.
    Rubinstein I; Patel M; Ikezaki H; Dagar S; Onyüksel H
    Peptides; 1999 Dec; 20(12):1497-501. PubMed ID: 10698126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of vasoactive intestinal peptide (VIP) on the testicular vasculature of the rat.
    Lissbrant E; Bergh A
    Int J Androl; 1997 Dec; 20(6):356-60. PubMed ID: 9568528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer.
    Onyüksel H; Mohanty PS; Rubinstein I
    Int J Pharm; 2009 Jan; 365(1-2):157-61. PubMed ID: 18793708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal vasoactive intestinal peptide.
    Sethi V; Onyüksel H; Rubinstein I
    Methods Enzymol; 2005; 391():377-95. PubMed ID: 15721392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions of human secretin with sterically stabilized phospholipid micelles amplify peptide-induced vasodilation in vivo.
    Gandhi S; Tsueshita T; Onyüksel H; Chandiwala R; Rubinstein I
    Peptides; 2002 Aug; 23(8):1433-9. PubMed ID: 12182944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal VIP attenuates phenylephrine- and ANG II-induced vasoconstriction in vivo.
    Ikezaki H; Onyüksel H; Rubinstein I
    Am J Physiol; 1998 Aug; 275(2):R588-95. PubMed ID: 9688697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary vascular effects of vasoactive intestinal peptide in the isolated perfused rat heart.
    Sawmiller DR; Henning RJ; Cuevas J; Dehaven WI; Vesely DL
    Neuropeptides; 2004 Oct; 38(5):289-97. PubMed ID: 15464194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasodilatory effect of the stable vasoactive intestinal peptide analog RO 25-1553 in murine and rat lungs.
    Yin J; Wang L; Yin N; Tabuchi A; Kuppe H; Wolff G; Kuebler WM
    PLoS One; 2013; 8(9):e75861. PubMed ID: 24069452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.